With its protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab showing strong anti-cholesterol results across patient populations and dosing schedules (monthly as well as every two weeks) in phase III trials, Amgen Inc. held fast against data provided thus far by Regeneron Pharmaceuticals Inc. with alirocumab, also targeting PCSK9.